BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 18, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Oct. 6, 2010
View Archived Issues
Cyclacel Seeks to Raise $22M for Phase III-Ready AML Drug
Read More
Biotechs Can Go Solo in Asian Markets, but Not Easy
Read More
Other News To Note
Read More
Stock Movers
Read More
Clinic Roundup
Read More
HGS, Novartis Bail on Zalbin After Thumbs Down from FDA
Upon receipt of a complete response letter from the FDA, Human Genome Sciences Inc. and Novartis AG have decided not to pursue Zalbin (albinterferon alfa-2b) in hepatitis C. (BioWorld Today)
Read More
Panel: Correctly Managing IP Essential to Biotech Success
Read More